Overview

Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
0
Participant gender:
All
Summary
Patients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of orthostatic hypotension, are eligible for the study. Each patient will have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Royal Brisbane and Women's Hospital
Treatments:
Domperidone
Fludrocortisone
Criteria
Inclusion Criteria:

- Patients residing in Queensland Australia

- Age 40-95

- Parkinson's Disease or MSA diagnosed by a neurologist

- Symptoms of orthostatic hypotension, as defined by 2 validated questionnaires

Exclusion Criteria:

- Patients with acute cardiomyopathy or cardiac condition

- Patients unable to give consent

- Patients not stable on their Parkinsonian medications

- Patients with another cause for autonomic neuropathy